| Patient | Friedrich Nietzsche |
|---|---|
| Date of birth | 1989-10-15 |
| Identifiers | MRN HR-NI019-SYN; SSN (made up) 000-19-5523 |
| Document date | 2026-08-04 |
| Author | Konrad Ellison-Mbatha, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Flashes of light and a new floater in the right eye since last evening. [S]
Mr. Nietzsche asked for a same-day visit because last evening he began to see brief arcs of light at the outer edge of the right eye's vision when he moved his eyes, most noticeable in dim light, and this morning a cobweb-like floater that drifts when he looks around. There is no shadow or curtain, no loss of vision beyond his usual poor right eye, and no pain. He has no headache with it, and it is unlike his migraine attacks, which have never had a visual aura. He is in the third week of the butalbital taper, taking one tablet every other day, and had his first galcanezumab injection two weeks ago. He has had no injury to the eye. [S]
| Element | Detail |
|---|---|
| Onset | Last evening |
| Location | Right eye only, outer field |
| Duration | Flashes of a second or less, repeatedly, since last evening; floater since this morning |
| Character | Arcs of light with eye movement; a cobweb-like floater |
| Severity | Not painful; alarming to him |
| Timing | With eye movement, worse in dim light |
| Context | High myopia; poor right eye; third week of the taper |
| Modifying factors | Not affected by covering the left eye |
| Associated signs and symptoms | No headache, curtain, shadow, pain or injury |
| System | Result | Finding |
|---|---|---|
| Eyes | Positive | Flashes and a floater in the right eye; no curtain, pain or redness |
| Neurological | Negative | No headache with the symptoms; no weakness, numbness or speech change |
| Constitutional | Negative | No fever |
3 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Butalbital 50 mg, acetaminophen 325 mg and caffeine 40 mg oral tablet, one or two tablets as needed for headache, taken on about 16 days a month, up to four tablets a day (prescribed abroad) | One or two tablets as needed, about 16 days a month, up to four a day | Oral route | 2025-11-03 to 2026-07-21 | stopped | S |
| Ibuprofen 200 mg oral tablet, two tablets as needed for headache on days without the combination tablets, about 4 days a month (over the counter) | Two tablets as needed, about 4 days a month | Oral route | 2025-11-03 to 2026-07-21 | stopped | S |
| Butalbital 50 mg, acetaminophen 325 mg and caffeine 40 mg oral tablet, scheduled taper: one tablet twice a day for 7 days, then one tablet a day for 7 days, then one tablet every other day for 7 days, then stop | Scheduled taper over three weeks: twice a day, then once a day, then every other day, then stop; not for extra doses | Oral route | 2026-07-21 to 2026-08-10 | completed | S |
| Naproxen 500 mg oral tablet, one tablet with food at the start of a migraine attack, may repeat once after 12 hours; no more than two days a week | One tablet at attack onset, may repeat once after 12 hours; no more than two days a week | Oral route | 2026-07-21 | active | S |
| Metoclopramide 10 mg oral tablet, one tablet with the acute medicine when a migraine attack brings nausea or vomiting; no more than two days a week | One tablet with the acute medicine when nausea is present, no more than once a day | Oral route | 2026-07-21 | active | S |
| Galcanezumab 120 mg/mL auto-injector, 240 mg (two injections) under the skin as a first loading dose, then 120 mg once a month, for chronic migraine prevention | Loading dose of 240 mg (two injections) on the first day, then 120 mg every four weeks | Subcutaneous route | 2026-07-21 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-08-04 | Body height | 174 | cm | S |
| 2026-08-04 | Body weight | 66.4 | kg | S |
| 2026-08-04 | Body mass index (BMI) [Ratio] | 21.9 | kg/m2 | S |
| 2026-08-04 | Systolic blood pressure | 116 | mm[Hg] | S |
| 2026-08-04 | Diastolic blood pressure | 74 | mm[Hg] | S |
| 2026-08-04 | Heart rate | 66 | /min | S |
| 2026-08-04 | Respiratory rate | 14 | /min | S |
| 2026-08-04 | Body temperature | 36.6 | Cel | S |
| 2026-08-04 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
Vital signs recorded on 2026-08-04; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; blood pressure 116/74, pulse 66 |
| Eyes | Visual acuity with contact lenses 20/100 right and 20/20 left, unchanged; right pupil 1 mm larger, both reacting briskly, no afferent defect; confrontation fields full; no redness. Dilated examination by the eye service: a Weiss ring in the right eye; no retinal break, detachment, vitreous hemorrhage or pigment in the anterior vitreous; the known myopic changes at the right macula are unchanged; left eye unchanged |
| Neurological | Normal |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Frequent disabling headaches on about 20 days a month, with nausea, vomiting and light sensitivity, mostly right-sided, since childhood and more frequent over the past year, with a combination headache tablet containing butalbital taken on about 16 days a month; under evaluation with a headache diary, MRI, syphilis serology and a headache medicine consultation | resolved | confirmed | R51.9 | S — Synthetic presenting problem anchored to his documented headaches; superseded when the consultation confirmed chronic migraine with medication overuse headache. |
| Chronic migraine without aura (15 or more headache days a month for more than three months, at least 8 with migraine features); ICHD-3 criteria met in a two-week diary; MRI of the brain normal; synthetic modern diagnosis linked to his documented headaches, which historians interpret differently | active | confirmed | G43.709 | S — Synthetic modern diagnosis made at the consultation; the historical diagnosis is disputed (CLM-0014), so this is not a claim about his real diagnosis. |
| Medication overuse headache from a butalbital, acetaminophen and caffeine combination on 10 or more days a month for more than three months, with ibuprofen on other days; resolved after a three-week taper and withdrawal | active | confirmed | G44.40 | S — Synthetic diagnosis made at the consultation, anchored to his documented use of many medicines and sedatives; not a claim about his real medicines. |
| High myopia in both eyes, much worse in the right eye, since early childhood, with long-standing poor vision in the right eye and unequal pupils; comprehensive eye examination booked | active | confirmed | H52.13 | S — Synthetic modern coding of his documented severe myopia. |
| Pathologic (degenerative) myopia of the right eye with patchy chorioretinal atrophy of the macula, a posterior staphyloma and a tilted optic disc; no choroidal neovascularization on OCT; best corrected vision 20/100 in the right eye | active | confirmed | H44.2E1 | S — Synthetic finding of the comprehensive eye examination, anchored to his documented poor right eye and the retrospective reading of it as myopic degeneration; not a claim about his real eyes. |
| Chronic insomnia, with difficulty falling asleep and early waking, worse on headache nights; no sleep medicine at intake | active | confirmed | G47.00 | S — Synthetic sleep problem anchored to his documented severe insomnia; not a claim about his real sleep. |
| Acute posterior vitreous detachment of the right eye, with flashes and a floater, without a retinal break, detachment or vitreous hemorrhage on dilated examination, in an eye with pathologic myopia | active | confirmed | H43.811 | S — Synthetic acute eye problem in a highly myopic eye; not a historical claim. |
Guideline basis: Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition (2018); Posterior Vitreous Detachment, Retinal Breaks, and Lattice Degeneration Preferred Practice Pattern (2025)
Follow-up: Four-week review in two weeks. Same-day eye care for the warning symptoms above. Next scheduled visit 2026-08-18: four-week review after starting galcanezumab and the taper: withdrawal, headache days, acute medicine and the second injection. [S]